---
title: "Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249549309.md"
description: "Wolwo Pharma announced that it has completed the clinical trial of the \"Artemisia Annua Pollen Allergen Sublingual Drops.\" The summary report indicates that the product has good safety in adult patients with allergic rhinitis, with the main adverse reactions being grade 1 and 2. After 2 years of treatment and monitoring after discontinuation, it has been confirmed that the drug effectively improves symptoms caused by Artemisia Annua/Artemisia Pollen and reduces the use of symptomatic medications, providing evidence for long-term clinical application"
datetime: "2025-07-22T09:42:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249549309.md)
  - [en](https://longbridge.com/en/news/249549309.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249549309.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/249549309.md) | [繁體中文](https://longbridge.com/zh-HK/news/249549309.md)


# Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launch

According to the Zhitong Finance APP, Wolwo Pharma (300357.SZ) announced that its product "Artemisia Annua Pollen Allergen Sublingual Drops" (hereinafter referred to as "the product") has completed the "Long-term Efficacy and Safety Evaluation of Artemisia Annua Pollen Allergen Sublingual Drops in Adult Patients with Allergic Rhinitis - A Multicenter, Open-label Clinical Trial" and has formed a clinical trial summary report.

The safety analysis results of this clinical trial showed good safety, with the severity of adverse reactions mainly at levels 1 and 2. The types of adverse reactions were highly consistent with the adult phase III clinical safety data of the product and the adverse reaction data in the drug instructions.

This clinical trial verified that the Artemisia Annua Pollen Allergen Sublingual Drops can effectively improve the symptoms of allergic rhinitis (or accompanied by conjunctivitis) caused by Artemisia Annua/Artemisia vulgaris pollen through a 2-year treatment and efficacy monitoring during the first pollen season after discontinuation, and reduce the use of symptomatic medications. This trial further revealed the sustained efficacy improvement during the long-term treatment process and the maintenance of efficacy after discontinuation, providing sufficient evidence for the clinical long-term application of the drug

### Related Stocks

- [Wolwo Pharma (300357.CN)](https://longbridge.com/en/quote/300357.CN.md)

## Related News & Research

- [Potentially recoverable oil at Namibia's Mopane field rises 57%, shareholder says](https://longbridge.com/en/news/281196633.md)
- [Sugar Prices Fall on Weakness in Crude Oil](https://longbridge.com/en/news/281402179.md)
- [Russian mariner held after Houthi Red Sea attack leaves Yemen for home](https://longbridge.com/en/news/281586000.md)
- [Dinosaur collagen used to create one-of-a-kind handbag](https://longbridge.com/en/news/281562253.md)
- [Crude Oil Prices Drop Below $100 as Traders Brace for Trump Speech](https://longbridge.com/en/news/281422847.md)